Fibrotic interstitial lung disease (fILD) is often diagnosed late and can be difficult to recognise in people with common respiratory or cardiac long-term conditions. We examined whether baseline routine blood-test profiles and leucocyte telomere length (LTL) identified groups at higher risk of subsequent hospital-...
G. Lough, L. Wain, A. Meffen et al.· ERJ Open Research· 0 citations
Evidence of shared genetic associations for fibrosis across organs is found, both at individual genetic loci and genome-wide, which highlights specific genes that may contribute to fibrosis across organs and diseases, which may facilitate the development of new therapies.
Ebrima Joof, T. Hernández-Beeftink, G. Parcesepe et al.· BMJ Connections Clinical Gen...· 0 citations
PKN2 loss drives fibroblast reprogramming and aberrant ECM remodelling, establishing PKN2 as an important regulator of pulmonary fibroblast homeostasis and tissue repair.
Catherine E. McMullan, Oscar A. Peña, P. Rajasekar et al.· bioRxiv· 0 citations
This work identifies proteins that are potentially therapeutic targets for respiratory disease, and which warrant follow-up for utility and safety, and adds to the literature identifying surfactant protein D as a candidate, yet predicts that integrin subunit alpha V (ITGAV) inhibition could impair some lung function me...
Jing Chen, N. Shrine, Kayesha Coley et al.· ERJ Open Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.